Decipher Genomics Resource for Intelligent Discovery
Launched by GENOMEDX BIOSCIENCES CORP · Nov 18, 2015
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Observational study involving the release of tumor genome-wide expression data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics of cancer and discover or validate gene expression signatures that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects that have had a Decipher clinical test
About Genomedx Biosciences Corp
Genomedx Biosciences Corp. is a leading clinical trial sponsor dedicated to advancing precision medicine through innovative genomic research and development. With a focus on harnessing cutting-edge technologies, the company aims to enhance disease understanding and improve patient outcomes by facilitating the discovery and commercialization of novel diagnostics and therapeutics. Genomedx Biosciences Corp. collaborates with healthcare professionals, researchers, and institutions to conduct rigorous clinical trials, ensuring the highest standards of scientific integrity and regulatory compliance. Their commitment to excellence and patient-centric approach positions them at the forefront of bioscience innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Tampa, Florida, United States
Baltimore, Maryland, United States
Miami, Florida, United States
San Francisco, California, United States
Indian Wells, California, United States
Evanston, Illinois, United States
Boston, Massachusetts, United States
Royal Oak, Michigan, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Elai Davicioni, PhD
Principal Investigator
Veracyte, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials